Author:
Chen Yan,Huang Ruibin,Ding Jianghua,Ji Dexiang,Song Bing,Yuan Liya,Chang Hong,Chen Guoan
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Sugumar, D., Keller, J. & Vij, R. Targeted treatments for multiple myeloma: specific role of carfilzomib. Pharmgenomics Pers Med 8, 23–33 (2015).
2. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–72 (2011).
3. Lohr, J. G. et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25, 91–101 (2014).
4. Ohashi, K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A 109, E2127–33 (2012).
5. Misale, S. et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 6, 224ra26 (2014).
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献